<?xml version='1.0' encoding='utf-8'?>
<document id="23589317"><sentence text="Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study." /><sentence text="To assess the pattern and probable risk factors for moderate and major drug-drug interactions in a referral hematology-oncology ward in Iran" /><sentence text="" /><sentence text="All patients admitted to hematology-oncology ward of Dr" /><sentence text=" Shariati Hospital during a 6-month period and received at least two anti-cancer or non-anti-cancer medications simultaneously were included" /><sentence text=" All being scheduled anti-cancer and non-anti-cancer medications both prescribed and administered during ward stay were considered for drug-drug interaction screening by Lexi-Interact On-Desktop software" /><sentence text="" /><sentence text="One hundred and eighty-five drug-drug interactions with moderate or major severity were detected from 83 patients" /><sentence text=" Most of drug-drug interactions (69" /><sentence text="73 %) were classified as pharmacokinetics" /><sentence text=" Fluconazole (25"><entity charOffset="1-12" id="DDI-PubMed.23589317.s11.e0" text="Fluconazole" /></sentence><sentence text="95 %) was the most commonly offending medication in drug-drug interactions" /><sentence text=" Interaction of sulfamethoxazole-trimethoprim with fluconazole was the most common drug-drug interaction (27"><entity charOffset="16-32" id="DDI-PubMed.23589317.s13.e0" text="sulfamethoxazole" /><entity charOffset="33-45" id="DDI-PubMed.23589317.s13.e1" text="trimethoprim" /><entity charOffset="51-62" id="DDI-PubMed.23589317.s13.e2" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.23589317.s13.e0" e2="DDI-PubMed.23589317.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23589317.s13.e0" e2="DDI-PubMed.23589317.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23589317.s13.e0" e2="DDI-PubMed.23589317.s13.e2" /><pair ddi="false" e1="DDI-PubMed.23589317.s13.e1" e2="DDI-PubMed.23589317.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23589317.s13.e1" e2="DDI-PubMed.23589317.s13.e2" /></sentence><sentence text="27 %)" /><sentence text=" Vincristine with imatinib was the only identified interaction between two anti-cancer agents"><entity charOffset="1-12" id="DDI-PubMed.23589317.s15.e0" text="Vincristine" /><entity charOffset="18-26" id="DDI-PubMed.23589317.s15.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.23589317.s15.e0" e2="DDI-PubMed.23589317.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23589317.s15.e0" e2="DDI-PubMed.23589317.s15.e1" /></sentence><sentence text=" The number of administered medications during ward stay was considered as an independent risk factor for developing a drug-drug interaction" /><sentence text="" /><sentence text="Potential moderate or major drug-drug interactions occur frequently in patients with hematological malignancies or related diseases" /><sentence text=" Performing larger standard studies are required to assess the real clinical and economical effects of drug-drug interactions on patients with hematological and non-hematological malignancies" /><sentence text="" /></document>